Next-generation anti-CD20 rituximab antibody that is engineered to be resistant to the immuno-suppressive effect mediated by the tumor-shed antigen, CA125
Ended Project Grant Awarded Last action
- Award ID
- R03CA241784
- Recipient
-
Navrogen Inc. UEI R5KFDECV7HW6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $69,000
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Place of performance
- Philadelphia, PA 19131, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $69,000 |
Quick answers
Who received award R03CA241784?
R03CA241784 was awarded to Navrogen Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2020.
How much is award R03CA241784 worth?
$69,000 has been obligated on R03CA241784.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award